GLP-1 Agonists Show Promise in Treating Patients with MASLD and Diabetes
A retrospective cohort study shows that GLP-1 agonists reduced the risk of cirrhosis and HCC in patients with MASLD and Type 2 diabetes.
A retrospective cohort study shows that GLP-1 agonists reduced the risk of cirrhosis and HCC in patients with MASLD and Type 2 diabetes.
Dr. Yin Cao’s research links factors such as obesity, metabolic syndrome, prolonged sitting, poor diet and sugar-sweetened beverages with early-onset colorectal cancer.
You don’t build a network by saying no — but you have to follow through, says Dr. Maria Abreu.
The guidelines recommend broad use of rectal NSAIDs to reduce the risk of post-ERCP pancreatitis.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.